Clinical Trials@2x
  • News

    Most Read

    • Mirum initiates enrolment in Phase IIb VISTAS study of volixibat for PSC
    • Knopp Biosciences reports positive trial results of oral asthma drug
    • Ampio completes 55atient enrolment in Covid-19 trial

    Most Recent

    Clinical Trials

    Mirum initiates enrolment in Phase IIb VISTAS study of volixibat for PSC

    15 Jan 2021
  • Analysis

    Sections

    • Features
    • Comment
    • Projects

    Most Read

    • Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy
    • Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market
    • Novo Nordisk’s makes strides into Alzheimer’s with anti-diabetic drug

    Most Recent

    Clinical Trials

    Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy

    12 Jan 2021
  • Sectors

    Sections

    • Clinical Trials
    • Approvals
    • Clinical Research
    • Operations
    • Outsourcing
    • Supply Chain
    • Cold Chain
    • Data Management
    • Medical Devices

    Most Read

    • Mirum initiates enrolment in Phase IIb VISTAS study of volixibat for PSC
    • AzurRx engages CROs Rho and Linical in separate Phase II trials in cystic fibrosis with pancreatic insufficiency
    • Revitope Oncology welcomes CRO and CMO pitches in several months for Phase I trial and drug development

    Most Recent

    Clinical Trials

    Mirum initiates enrolment in Phase IIb VISTAS study of volixibat for PSC

    15 Jan 2021
  • Themes
  • Deals

    Most Read

    • Investment firm GI Partners closes Clinical Ink acquisition
    • Investment firm GI Partners to acquire minority interest in Clinical Ink
    • IVI and SNU partner to trial Inovio’s Covid-19 vaccine in Korea

    Most Recent

    Clinical Trials

    Investment firm GI Partners closes Clinical Ink acquisition

    27 Aug 2020
  • Companies

    Sections

    • Company A-Z
    • Company Categories
    • Products & Services
    • Company Releases
    • White Papers
    • Videos

    Most Read

    • OpenClinica
    • Strategikon Pharma
    • IVR Clinical Concepts

    Most Recent

    Clinical Trials

    OpenClinica

    30 Dec 2020
  • Magazine
  • Events
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Approvals
    • Clinical Research
    • Operations
    • Outsourcing
    • Supply Chain
    • Cold Chain
    • Data Management
    • Medical Devices
  • Deals
  • Tech
  • Disruption
  • Coronavirus
Partners
  • Accelerating Clinical Trials
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register
AiCuris finds chronic hepatitis B drug candidate safe in Phase I trial

AiCuris finds chronic hepatitis B drug candidate safe in Phase I trial

German drug development company AiCuris Anti-infective Cures has reported positive results from the Phase I...

4th September 2018

Latest News

Clinical Trials

Mirum initiates enrolment in Phase IIb VISTAS study of volixibat for PSC

15 Jan 2021
Clinical Trials

Knopp Biosciences reports positive trial results of oral asthma drug

15 Jan 2021
Clinical Trials

Ampio completes 55% patient enrolment in Covid-19 trial

15 Jan 2021
Clinical Trials

Terns concludes patient enrolment in NASH treatment trial

13 Jan 2021

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
Clinical Trials

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms and Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more